DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Serzone is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in SERZONE is nefazodone hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nefazodone hydrochloride profile page.
A generic version of SERZONE was approved as nefazodone hydrochloride by TEVA on September 16th, 2003.
Recent Clinical Trials for SERZONE
Identify potential brand extensions & 505(b)(2) entrants
|Boston Medical Center||Phase 2|
|Boston University||Phase 2|
|Country||Patent Number||Estimated Expiration|
|Greece||76076||Get Started for $10|
|Sweden||8201631||Get Started for $10|
|Japan||H0524151||Get Started for $10|
|Denmark||112582||Get Started for $10|
|Hong Kong||4788||Get Started for $10|
|Mexico||9203176||Get Started for $10|
|Japan||H0237353||Get Started for $10|
|>Country||>Patent Number||>Estimated Expiration|